S2 Episode 2: Should All Newly Diagnosed Multiple Myeloma Patients Be Treated With a Quadruplet in Frontline Therapy?

S2 Episode 2: Should All Newly Diagnosed Mult...

MEDSCAPEMEDSCAPE

Up next

S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ...  Show more

 . 24min 38sec
S2 Episode 4: Should You Treat Smoldering Multiple Myeloma?

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent studies and shared decision-making. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002716. The ...  Show more

 . 24min 51sec

Recommended Episodes

S1 Episode 6: New and Emerging Therapies in HIV Treatment
Medscape InDiscussion: HIV

Drs Michael Saag and Judith Currier discuss options for long-acting HIV therapies, minimizing patient interactions with the healthcare system, and honoring patient preferences. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/vie ...  Show more

 . 21min 17sec
S1 Episode 3: Antiretroviral Therapy, Maintenance, and Switching
Medscape InDiscussion: HIV

Drs Michael Saag and Constance Benson discuss antiretroviral therapy, maintenance, and switching. Relevant disclosures can be found with the episode show notes on Medscape.com ( https://www.medscape.com/viewarticle/963238). The topics and discussions are planned, produced, and rev ...  Show more

 . 22min 31sec
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

 . 1h 0min
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
Blood Podcast

In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ...  Show more

 . 20min 5sec